Xencor’s experimental drug shows promise Xencor Inc.’s experimental treatment for a rare immune disorder helped reduce the severity of the disease for 82 percent of patients, according to data from a midstage trial that the company presented at a weekend conference. Nine of 11 patients with immunoglobin G4-related disease, an inflammatory disorder...